Sustained immunological effects of Glatiramer acetate in patients with multiple sclerosis treated for over 6 years

Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis

K. P. Johnson, Benjamin Brooks, J. A. Cohen et al. · Neurology · 1995 · 1.9K citations

Pharmacy, Neurology, Pharmacotherapy +15

General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids.

Richard A. Houghten · Proceedings of the National Academy of Sciences · 1985 · 1.7K citations · Full text

Life Sciences, Biochemistry, Molecular Biology +14

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.

Giancarlo Comi, Massimo Filippi, Jerry S. Wolinsky · PubMed · 2001 · 691 citations

Pharmacy, Neurology, Pharmacotherapy +14

European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis

Giancarlo Comi, Massimo Filippi, Jerry S. Wolinsky · Annals of Neurology · 2001 · 608 citations

Medicine, Neurology, Pharmacotherapy +15

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability

K. P. Johnson, Benjamin Brooks, J. A. Cohen et al. · Neurology · 1998 · 512 citations

Pharmacy, Pharmacology, Pharmacotherapy +12